

This article was downloaded by:

On: 28 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

SYNTHESIS OF SULFUR ANALOGUES OF CYCLIC PHOSPHOLIPID CONJUGATED WITH N¹-(2-FURANIDYL)-N³-(2-HYDROXYETHYL)-5-FLUOROURACIL

Chengxiang Zhang^a; Ruyu Chen^a; Chuchi Tang^a; Zhongbiao Zhang^a

^a Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, China

To cite this Article Zhang, Chengxiang , Chen, Ruyu , Tang, Chuchi and Zhang, Zhongbiao(1998) 'SYNTHESIS OF SULFUR ANALOGUES OF CYCLIC PHOSPHOLIPID CONJUGATED WITH N¹-(2-FURANIDYL)-N³-(2-HYDROXYETHYL)-5-FLUOROURACIL', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 132: 1, 155 — 161

To link to this Article: DOI: 10.1080/10426509808036983

URL: <http://dx.doi.org/10.1080/10426509808036983>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF SULFUR ANALOGUES OF CYCLIC PHOSPHOLIPID CONJUGATED WITH N¹-(2-FURANIDYL)-N³- (2-HYDROXYETHYL)-5-FLUOROURACIL

CHENGXIANG ZHANG*, RUYU CHEN, CHUCHI TANG
and ZHONGBIAO ZHANG

Institute of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, China

(Received 1 July, 1997; In final form 1 October, 1997)

Two types of cyclic polythiophospholipid conjugated with N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil were synthesized. The hexaethyl phosphorous triamide, activated by a catalytic amount of iodine, was used as the phosphorylating reagent in a one-pot reaction resulting in a number of novel phospholipid-drug conjugates.


Keywords: Cyclic Polythiophospholipids; 5-Fluorouracil Derivatives; Conjugates; Hexaethylphosphorous Triamide

INTRODUCTION


Phospholipid-nucleoside conjugates have demonstrated potent antitumor activity *in vitro* and *in vivo*.^{1,2,3} In a previous paper, we have described the synthesis and antitumor activities of cyclic phospholipid-nucleoside conjugates.^{4,5} As an extension of our work, this paper describes the synthesis of sulfur analogues of cyclic phospholipid conjugates of 5-fluorouracil derivatives. We became interested in sulfur-containing cyclic phospholipids since these compounds tend to be more lipophilic than their oxygen counterparts. Thus they may be more easily inserted into membranes and thus disrupt the membrane function.^{6,7} At the same time the conjugates may generate two cytotoxic groups inside a neoplastic cell of a different target site: membrane and the synthesis of DNA.⁶ N¹-(2-furanidyl)-fluorouracil (Tegafur) is a potent inhibitor of mammalian cell in clinical use, however, its side effects, such as hot sensation and pollakiuria syndrome, encour-

* Corresponding Author.


age people to develop a better drug.⁸ So the aim is to synthesize the polythiosubstituted phospholipid conjugates of 5-fluorouracil derivatives.




SCHEME 1



SHCHEME 2



SCHEME 3



SCHEME 4

RESULTS AND DISCUSSION


Tegafur(**1**) is one of the 5-fluorouracil antitumor agents. In order to improve its antitumor activity and reduce its side-effects, we attempted to synthesize its conjugates of cyclic polythiophospholipids. According to **Scheme 1**, the alkylation of tegafur with β -bromoethanol was carried out as described in a previous paper.⁴

Scheme 2 describes the synthesis of N-(2, 3-dimercaptopropyl) palmitoylamide(**4**). Allyl amine reacted with palmitoyl chloride in the presence of pyridine to give compound **2** which reacted with bromine in chloroform to give compound **3** in nearly quantitative yield. The bromo groups in compound **3** were converted to mercaptan in compound **4** by means of potassiummethylxanthate as sulfurizing reagent.

Scheme 3 describes the synthesis of 2, 3-dimercaptopropyl dodecyl sulfide(**7**). 3-Bromopropene was reacted with 1-dodecanethiol to yield compound **5**. Compound **5** was converted to compound **7** by the same procedure.

Compounds **9** and **10** were obtained by a one-pot(two-step) reaction from β -hydroxyethyl tegafur(**1**) by means of hexaethyl phosphorous triamide, activated by iodine, as a phosphorylating reagent under mild conditions (**Scheme 4**). Thus the activated phosphorous triamide was reacted with compound **1** in stoichiometric amounts at 65°C to give the bis(N, N-diethylamido)-phosphite (**8**) in nearly quantitative yield. This was proven by transformation of **8** to the corresponding thiophosphate derivative **11**. The consecutive treatment of the intermediate **8** with an equivalent amounts of the dimercapto compounds and sulfur at 65°C for 4h and 30min respectively afford the compound **9** and **10**, which were isolated by column chromatography separately.

In the ³¹PNMR spectra of the target compounds **9** and **10**, doublets are presented in the spectra of the cyclic thiophosphates. this phenomena could be explained as below. The synthesized compounds may be discussed as 4-substituted 1, 3, 2-dithiaphospholane derivatives, the cyclic derivatives contain two additional chiral centers(CH and P), thus the target compounds may have two pairs of diastereoisomers[(R, R)-(S, S)] and [(R, S)-(S, R)] (Fig. 1). The different intensity of the signals could be explained by the thermodynamically defined predominance of some of the assumed conformers. A steric induction resulting from the chiral exocyclic fragment may be considered another reason for the ³¹PNMR spectral anisochronicity detected. Our results are in agreement with those reported in the literature for analogous systems.^{9,10} Further study on the physical properties and biological activities of the cyclic thiophosphates are under way.



9 : X=NH, R=CH₃(CH₂)₁₄CO; R'= fluorouracil derivative

10: X=S, R=CH₃(CH₂)₁₁ ; R'= fluorouracil derivative

FIGURE 1

EXPERIMENTAL

IR spectra were recorded on a NICOLET 5DX instrument. NMR spectra were taken on a BRUKER AC-P200 spectrometer, TMS being used as an internal standard for ¹HNMR and 85% H₃PO₄ as an external standard for ³¹PNMR spectroscopy. Elemental analyses were carried out with a YANACO CHN CORDER MT-3 elementary analyser. Melting points are uncorrected. Benzene and pyridine were distilled from sodium and potassium hydroxide, respectively, before being used. Petroleum ether refers to a fraction of b.p. 60–90 °C. Column chromatography was carried out with silica gel H(10–40 μm). Hexaethylphosphorous triamide was prepared according to the literature¹¹ and freshly distilled.

N-Allyl palmitoylamide(2)

A solution of 2.4mL(8mmol)of palmitoyl chloride and 1.3mL (18mmol) of allylamine in 50mL of diethyl ether was stirred for 24h at room temperature. The solution was washed with water, 5% hydrochloric acid and water, then dried over Na₂SO₄. The solvent was evaporated, and the residue was recrystallized from diethyl ether to yield a white solid(2.0g, 84%).m.p. 82–84°C ; C₁₉H₃₇NO. Calcd: C, 77.29; H, 12.54; N, 4.75, Found: C, 77.32, H 12.48, N, 4.78. ¹HNMR(CDCl₃) δ 0.86(3H, t, CH₃), 1.28(24H, brs, (CH₂)₁₂), 1.59(2H, m, CH₂CH₂CO), 2.18(2H, t, CH₂CO), 3.40–4.10(5H, m, CH₂CHCH₂).

N-(2, 3-Dibromopropyl) palmitoylamide (3)

To a solution of 1.5g (5mmol) of N-allyl palmitoylamide(2) in 20mL of chloroform, a solution of 0.26mL (5mmol) of bromine in 5mL chloroform was added dropwise at 0°C. The mixture was allowed to come to room temperature and stirred further for 20min at 50°C. The solvent was evaporated and the residue was recrystallized from diethyl ether to yield a white solid (1.9g, 94%), m.p. 84–86°C; $C_{19}H_{37}Br_2NO$. Calcd: C, 50.11; H, 8.13; N, 3.08, Found: C, 50.21; H, 8.13, N, 2.99. 1H NMR($CDCl_3$) δ 0.84 (3H, t, CH_3), 1.22 (24H, brs, $(CH_2)_{12}$), 1.61 (2H, m, CH_2CH_2CO), 2.20 (2H, t, CH_2CO), 3.30–3.98 (4H, m, CH_2CHCH_2), 4.60 (1H, quint, CH), 5.60–5.80 (1H, d, NH).

N-(2, 3-dimercaptopropyl) palmitoylamide(4)

A solution of 4.0g (10 mmol) of N-(2, 3-dibromo propyl) palmitoyl amide(3) and 1.6g (10 mmol) potassium ethylxanthate in 50mL of ethanol (95%) was stirred for 4 days at room temperature, 5mL of aqueous ammonia (28%) was added and the mixture was stirred for 5h at 50°C. The solvent was evaporated and the residue was recrystallized from ethanol to yield a pale yellow solid (3.2g, 88%). m.p. 90–92°C; $C_{19}H_{39}NOS_2$. Calcd: C, 63.15; H, 10.80; N, 3.88, Found: C, 63.10; H, 10.50, N, 4.02. 1H NMR($CDCl_3$) δ 0.85 (3H, t, CH_3), 1.22 (24H, brs, $(CH_2)_{12}$), 1.61 (2H, 2H, CH_2CH_2CO), 2.20 (2H, t, CH_2CO), 3.50–4.20 (4H, m, CH_2CHCH_2), 4.60 (1H, quint, CH), 5.95 (1H, brs, NH).

2, 3-Dibromopropyl dodecyl sulfide (6)

A solution of 3.3g (10 mmol) of dodecanethiol and 0.56 (10 mmol) of potassium hydroxyl in 30mL of ethanol (95%) was stirred for 30min at room temperature. A solution of 0.74g (10 mmol) of allyl mercaptan in 20mL of ethanol (95%) was added and the mixture was stirred for 48h at room temperature. The solvent was evaporated and the residue was dissolved in 40mL of chloroform, a solution of 0.52g (10 mmol) of bromine in 10mL of chloroform was added dropwise at 0°C. The mixture was allowed to come to room temperature and stirred further for 20min at 50°C. The solvent was evaporated and the residue was chromatographed by silica gel column using petroleum ether as eluent. A colorless oily product (3.6g, 90%) was obtained. Rf value: 0.80 (petroleum ether); $C_{15}H_{30}Br_2S$. Calcd: C, 44.78; H, 7.46, Found: C, 44.72; H, 7.30. 1H NMR($CDCl_3$) δ 0.85 (3H, t, CH_3), 1.22 (18H, brs, $(CH_2)_9$), 1.60 (2H, m, CH_2CH_2S), 2.54 (2H, t, CH_2S), 3.18–4.00 (4H, m, CH_2CHCH_2), 4.22 (1H, quint, CH).

2, 3-dimercaptopropyl dodecyl sulfide(7)

A solution of 4.0g (10 mmol) of 2, 3-dibromopropyl dodecyl sulfide and 1.6g (10 mmol) potassium ethylxanthate in 50mL of ethanol (95%) was stirred for 4 days at room temperature, 5mL of aqueous ammonia (28%) was added and the mixture was stirred for 5h at 50°C. The solvent was evaporated and the residue was chromatographed by silica gel column using petroleum ether as eluent. A colorless oily product (2.2g, 74%) was obtained. R_f value: 0.50 (petroleum ether); C₁₅H₃₂S₃. Calcd: C, 58.44; H, 10.39, Found: C, 58.20; H, 10.30. ¹HNMR(CDCl₃) δ 0.85 (3H, t, CH₃), 1.22(18H, brs, (CH₂)₉), 1.60(2H, m, CH₂CH₂S), 2.54(2H, t, CH₂S), 2.80~3.40(5H, m, CH₂CHCH₂).

2-[1-(N¹-(2-furanidyl)-5-fluorouracil-N³-)ethyl-2-O-]-2-thio-4-palmitoylamino methyl-1, 3, 2-dithiaphospholane (9)

A mixture of iodine (0.026 g, 0.1 mmol) and tris(N, N-diethyl)amide of phosphorus acid (0.519 g, 2.1 mmol) in benzene (50 mL) was heated at 65 °C in a stream of nitrogen for about 15 min. After the precipitate had dissolved, N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil (1) (0.490 g, 2.0 mmol) was added and the reaction system was heated at 65 °C for 3 hr. N-(2, 3-dimercaptopropyl) palmitoylamide(4) (0.640 g, 2.0 mmol) was then added, and the reaction mixture was heated at 65 °C for another 3 h. Sulfur (0.067 g, 2.1 mmol) was added and the reaction system was kept under the same conditions for 30 min. The solvent was evaporated *in vacuo*, and the residue was chromatographed by use of a silica gel column with petroleum ether-ethyl acetate (1:1, V/V) as the eluent. A colorless oily product (0.67 g, 50%) was obtained. R_f value: 0.60 (petroleum ether/ethyl acetate, V/V, 1:1). C₂₉H₄₉FN₃O₅PS₃. Calcd: C, 52.33; H, 7.37; N, 6.32. Found: C, 52.52; H, 7.52; N, 6.59. IR (liq): 2914, 1718, 1689, 1378, 1264, 1234, 1067, 1018, 962, 878, 697cm⁻¹; ¹HNMR (CDCl₃): δ 0.83 (3H, t, CH₃), 1.20 (24H, brs, (CH₂)₁₂), 1.51 (2H, m, OCCH₂CH₂), 1.79~2.46 (4H, m, 3',4'-CH₂), 2.33 (2H, t, CH₂CO), 3.05~3.28 (4H, m, CH₂CHCH₂), 3.98(1H, m, 5'-H_a), 4.02~4.33 (6H, m, 5'-H_b, CH₂CHCH₂, OCH₂CH₂N), 5.92(1H, brs, 2'-H), 7.35(1H, d, J_{HF}=5.4Hz, 6-H), 9.60(1H, brs, NH); ³¹PNMR (CDCl₃, δ): 84.61, 84.37ppm(each d).

2-[1-(N¹-(2-furanidyl)-5-fluorouracil-N³-)ethyl-2-O-]-2-thio-4-dodecyl mercapto methyl-1, 3, 2-dithiaphospholane (10)

Using N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil (2) (0.490g, 2.0 mmol) and 2, 3-dimercaptopropyl dodecyl sulfide (0.620 g, 2.0 mmol), com-

pound **10** was synthesized and then purified in the same way as described for compound **9**. A pale yellow oily product (0.71 g, 58%) was obtained. R_f value: 0.65 (petroleum ether/ethyl acetate, 1 : 1, V/V). C₂₅H₄₂FN₂O₄PS₄. Calcd.: C, 49.02; H, 6.86; N, 4.57. Found: C, 48.95; H, 6.74; N, 4.48. IR(liq.): 1718, 1689, 1660, 1460, 1378, 1264, 1062, 1018, 967, 878, 718, 697 cm⁻¹; ¹HNMR (CDCl₃): δ 0.85 (3H, t, J=6.0Hz, CH₃), 1.22 (18H, brs, (CH₂)₉), 1.58 (2H, m, SCH₂CH₂), 1.79~2.46 (4H, m, 3',4'-CH₂), 2.55 (2H, t, CH₂S), 2.80~3.20 (4H, m, CH₂CHCH₂), 3.95~4.20 (7H, m, 5'-CH₂, OCH₂CH₂N, CH₂CHCH₂), 5.96 (1H, brs, 2'-H), 7.35 (1H, d, J_{HF}=5.4Hz, 6-H); ³¹PNMR (CDCl₃, δ): 83.58, 83.68 ppm (each d).

**1-O-(N¹-(2-furanidyl)-5-fluorouracil-N³-)ethyl-bis(N,
N-diethyl-amido)-thiophosphate (11)**

A mixture of iodine (0.026 g, 0.1 mmol) and tris(N, N-diethyl)amide of phosphorus acid (0.519 g, 2.1 mmol) in benzene (50 mL) was heated at 65 °C in a stream of nitrogen for about 15 min. After the precipitate had dissolved, N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil (**1**) (0.490 g, 2.0 mmol) was added and the reaction system was heated at 65 °C for 3 hr. Then sulfur (0.067 g, 2.1 mmol) was added and the reaction system was kept under the same conditions for 30 min. The solvent was evaporated *in vacuo*, and the residue was chromatographed by use of a silica gel column with ethyl acetate as the eluent. A colorless oily product (0.72 g, 83%) was obtained. R_f value: 0.35 (ethyl acetate). C₁₈H₃₂FN₄O₀PS. Calcd: C, 48.00; H, 7.11; N, 12.44. Found: C, 47.82; H, 7.05; N, 12.59. ¹HNMR (CDCl₃): δ 1.02(12H, t, 4CH₃), 1.79~2.46(4H, m, 3',4'-CH₂), 3.11(8H, q, 4CH₂), 3.84(2H, t, NCH₂), 3.99(1H, m, 5'-H_a), 4.19(2H, t, OCH₂), 4.20(1H, m, 5'-H_b), 5.96(1H, brs, 2'-H), 7.40(1H, d, J_{HF}=5.4Hz, 6-H). ³¹PNMR (CDCl₃, δ): 77.6.

References

- [1] T. Matsushita, E. K. Ryu, C. I. Hong, *Cancer Res.* **41**, 2707(1981).
- [2] C. I. Hong, A. J. Kirisits, A. Nechaev, et al, *J. Med. Chem.* **33**, 1380(1990).
- [3] J. G. Turcotte, S. P. Srivastava, W. A. Meresak, et al, *Biochim. Biophys. Acta.* **619**, 604(1980).
- [4] C. X. Zhang, R. Y. Chen, C. C. Tang, et al, *Heteroatom Chem.* **9**(3), 295 (1998).
- [5] C. X. Zhang, Z. B. Zhang, C. C. Tang, H. M. Chen, R. Y. Chen, *Chem. J. Chin. Univ.* **18**(11), 1809 (1997).
- [6] C. I. Hong, C. R. West, R. J. Bernaki, C. K. Chu, *J. Lipid Mediators Cell Signalling*, **10**(1-2), 159(1994).
- [7] S. L. Morris-Natschke, J. R. Surles, L. W. Daniel, M. E. Berens, E. J. Modest, *J. Med. Chem.* **29**, 2114(1986).
- [8] M. Yasumoto, I. Yamawaki, T. Marunaka, S. Hashimoto, *J. Med. Chem.* **21**, 738(1978).
- [9] S. D. Stamatov and S. Gronowitz, *Chem. Phys. Lipids.* **58**, 193(1991).
- [10] R. Y. Chen, M. Zhang, *Science in China(Series B)*, **24**, 113(1994).
- [11] A. B. Burg and P. J. Slota, *J. Am. Chem. Soc.* **80**, 1107(1958).